B
삼익제약
014950KOSDAQ61.3 / 100
Reference Date: 2026-09-08
Financial Score17.5 / 40
News Sentiment18.8 / 25
Momentum15.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 73.9% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Samik Pharmaceutical focuses on specialty pharmaceuticals, primarily synthetic drugs, and also operates a CMO business. The company develops products targeting major chronic diseases such as hypertension, diabetes, and hyperlipidemia, with circulatory system drugs accounting for 46.8% of revenue in 2025. It also conducts R&D on natural product-derived new drugs and improved formulations to enhance competitiveness.
Number of Employees
146people
Average Salary
54.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.28Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
-1.25Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
6.51Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 3.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
0.0 / 4
Detailed News Sentiment
2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 75
- PositiveJW신약·현대약품… ‘탈모주’ 급등
JW신약과 현대약품의 탈모 치료제 관련 급등으로 삼익제약의 주가가 긍정적 영향을 받음.
- Negative[마감시황]코스닥, 외국인·기관 매도에 821.25 마감…이틀 연속 하...
코스닥 하락으로 삼익제약 주가에도 부정적 영향 예상.
Detailed Momentum
52-week position3.0Point
52w lower range (28%)
Current 8,780Won52-week high 21,30052-week low 3,850
1-month return6.0Point
1m +73.86% (strong rise)
Volume trend6.0Point
Volume surge
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral반기보고서 (2026.06)2026-08-14